Alberto Migliore, Gianfranco Gigliucci, Lyudmila Alekseeva, Raveendhara R Bannuru, Tomasz Blicharski, Demirhan Diracoglu, Athanasios Georgiadis, Hesham Hamoud, Natalia Martusevich, Marco Matucci Cerinic, Jan Perduk, Imre Szerb, Tomáš Trč, Xavier Chevalier
{"title":"Systematic Literature Review and Expert Opinion for the Use of Viscosupplementation with Hyaluronic Acid in Different Localizations of Osteoarthritis.","authors":"Alberto Migliore, Gianfranco Gigliucci, Lyudmila Alekseeva, Raveendhara R Bannuru, Tomasz Blicharski, Demirhan Diracoglu, Athanasios Georgiadis, Hesham Hamoud, Natalia Martusevich, Marco Matucci Cerinic, Jan Perduk, Imre Szerb, Tomáš Trč, Xavier Chevalier","doi":"10.2147/ORR.S336185","DOIUrl":null,"url":null,"abstract":"<p><p>Osteoarthritis (OA) is a significant cause of disability. Considering the increasing diffusion of the viscosupplementation (VS) with hyaluronic acid (HA), the International Symposium Intra Articular Treatment (ISIAT) appointed a Technical Expert Panel (TEP) to identify the criteria for successful VS with a specific HA in OA; this through a systematic literature review (SLR), performed following the PRISMA guidelines interrogating Medline, Embase, Cochrane Library, Cumulative Index to Nursing and Allied Health Literature (CINAHL), Grey Matters and American College of Rheumatology (ACR/EULAR) databases and the opinion of international experts. The research included only studies on adults and humans without limitations of language or time of publication. Researchers extracted both quantitative and qualitative data from each study. Mixed Methods Appraisal Tool (MMAT) was used to perform quality analysis for the level of evidence. The SLR retrieved 385 papers, 25 of which were suitable for the analysis. The TEP focused on the different formulations of the product Sinovial<sup>®</sup> [HA 0.8%, HA 1.6%, HA 2%, 800-1200 kDa, HA 3.2% (1400-2100 kDa/65-110 kDa)]. The choice was due to the vast amount of evidence available. The TEP weighed the evidence in two rounds of a Delphi survey; the results, and any disagreement, were discussed in a final session. Three domains were considered: 1) the patients' characteristics associated with the best results; 2) the contraindications and the conditions linked to increased risk of failure; 3) the clinical conditions in which VS is considered appropriate. The TEP concluded that VS with HA is safe and effective in the treatment of knee and hip OA of grades I to III and that it is possible to undertake VS in other situations (eg grade IV Kellgren-Lawrence - KL); a comprehensive examination of the patient should be performed before the procedure.</p>","PeriodicalId":19608,"journal":{"name":"Orthopedic Research and Reviews","volume":"13 ","pages":"255-273"},"PeriodicalIF":1.7000,"publicationDate":"2021-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/70/cc/orr-13-255.PMC8648269.pdf","citationCount":"13","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Orthopedic Research and Reviews","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/ORR.S336185","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ORTHOPEDICS","Score":null,"Total":0}
引用次数: 13
Abstract
Osteoarthritis (OA) is a significant cause of disability. Considering the increasing diffusion of the viscosupplementation (VS) with hyaluronic acid (HA), the International Symposium Intra Articular Treatment (ISIAT) appointed a Technical Expert Panel (TEP) to identify the criteria for successful VS with a specific HA in OA; this through a systematic literature review (SLR), performed following the PRISMA guidelines interrogating Medline, Embase, Cochrane Library, Cumulative Index to Nursing and Allied Health Literature (CINAHL), Grey Matters and American College of Rheumatology (ACR/EULAR) databases and the opinion of international experts. The research included only studies on adults and humans without limitations of language or time of publication. Researchers extracted both quantitative and qualitative data from each study. Mixed Methods Appraisal Tool (MMAT) was used to perform quality analysis for the level of evidence. The SLR retrieved 385 papers, 25 of which were suitable for the analysis. The TEP focused on the different formulations of the product Sinovial® [HA 0.8%, HA 1.6%, HA 2%, 800-1200 kDa, HA 3.2% (1400-2100 kDa/65-110 kDa)]. The choice was due to the vast amount of evidence available. The TEP weighed the evidence in two rounds of a Delphi survey; the results, and any disagreement, were discussed in a final session. Three domains were considered: 1) the patients' characteristics associated with the best results; 2) the contraindications and the conditions linked to increased risk of failure; 3) the clinical conditions in which VS is considered appropriate. The TEP concluded that VS with HA is safe and effective in the treatment of knee and hip OA of grades I to III and that it is possible to undertake VS in other situations (eg grade IV Kellgren-Lawrence - KL); a comprehensive examination of the patient should be performed before the procedure.
骨关节炎(OA)是导致残疾的重要原因。考虑到透明质酸(HA)粘质补充剂(VS)的日益普及,国际关节内治疗研讨会(ISIAT)任命了一个技术专家小组(TEP)来确定OA中特定HA成功VS的标准;这是通过系统文献综述(SLR),按照PRISMA指南进行,询问Medline、Embase、Cochrane图书馆、护理和相关健康文献累积索引(CINAHL)、Grey Matters和美国风湿病学会(ACR/EULAR)数据库以及国际专家的意见。这项研究只包括对成年人和人类的研究,没有语言和发表时间的限制。研究人员从每项研究中提取定量和定性数据。采用混合方法评价工具(MMAT)对证据水平进行质量分析。SLR检索到385篇论文,其中25篇适合分析。TEP集中于产品Sinovial®的不同配方[HA 0.8%, HA 1.6%, HA 2%, 800-1200 kDa, HA 3.2% (1400-2100 kDa/65-110 kDa)]。这一选择是由于有大量可用的证据。TEP在两轮德尔菲调查中权衡了证据;结果和任何分歧都是在最后一次会议上讨论的。考虑三个领域:1)与最佳结果相关的患者特征;2)与失败风险增加相关的禁忌症和情况;3)认为VS合适的临床条件。TEP的结论是,HA联合VS治疗I至III级膝关节和髋关节OA是安全有效的,并且在其他情况下也可以进行VS(例如IV级kellgreen - lawrence - KL);手术前应对病人进行全面检查。
期刊介绍:
Orthopedic Research and Reviews is an international, peer-reviewed, open-access journal focusing on the patho-physiology of the musculoskeletal system, trauma, surgery and other corrective interventions to restore mobility and function. Advances in new technologies, materials, techniques and pharmacological agents will be particularly welcome. Specific topics covered in the journal include: Patho-physiology and bioengineering, Technologies and materials science, Surgical techniques, including robotics, Trauma management and care, Treatment including pharmacological and non-pharmacological, Rehabilitation and Multidisciplinarian care approaches, Patient quality of life, satisfaction and preference, Health economic evaluations. The journal welcomes submitted papers covering original research, basic science and technology, clinical studies, reviews and evaluations, guidelines, expert opinion and commentary, case reports and extended reports.